Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brilanestrant - Genentech

Next Previous
Drug Profile

Brilanestrant - Genentech

Alternative Names: ARN 810; GDC-0810; RG 6046; RO-7056118

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aragon Pharmaceuticals
  • Developer Genentech
  • Class Antineoplastics; Carboxylic acids; Chlorobenzenes; Fluorobenzenes; Indazoles; Small molecules
  • Mechanism of Action Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HER2 negative breast cancer

Most Recent Events

  • 13 Mar 2020 Genentech terminates a phase II trial in Her2-negative-breast-cancer (Locally recurrent, Metastatic disease) in South Korea, Spain, Netherlands, USA due to sponsor's decision to halt the development of brilanestrant (PO) (NCT01823835)
  • 28 Feb 2020 Genentech terminates a phase II trial for Her2-negative-breast-cancer (Metastatic disease) in USA, Spain, Germany, Australia, South Korea, and the UK (NCT02569801)
  • 30 Jan 2018 Chemical structure information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top